Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab

Boston, MA 10/03/2014 (wallstreetpr) – Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed out that the treatment with novel investigational low-density lipoprotein cholesterol or LDL-C, evolocumab, resulted in a statistically important reduction in LDL-C. The data compared with the placebo in patients affected […]